Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom CEO Steps Down

NEW YORK (GenomeWeb) – Bill Welch has resigned as Sequenom's president, CEO, and director "to pursue other interests," the company said today.

Dirk van den Boom is replacing him as interim president and CEO while retaining his role as chief scientific and strategy officer.

Welch became Sequenom's CEO just a year ago in June 2014, replacing Harry Hixson, who retired at the time. Welch had joined Sequenom in 2011 as senior vice president for diagnostics and became the company's president and COO in 2012.

Van den Boom became Sequenom's chief scientific and strategy officer in June 2014. Prior to that, he served as the firm's executive vice president for R&D and CSO, and before that, he was senior vice president for R&D and CTO. He joined Sequenom in 1998 at the company's Hamburg office in Germany. He holds a PhD in biochemistry and molecular biology from the University of Hamburg.

In Monday morning trade on the Nasdaq, shares of Sequenom were down 5 percent at $2.27.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.